An Analysis of BMP1 Associated with m6A Modification and Immune Infiltration in Pancancer

Abstract

Background. This research explores the underlying link between diagnosis and therapy between bone morphogenetic protein 1 (BMP1) and various cancers. Methods. Three immunotherapeutic cohorts, by the composition of IMvigor210, GSE35640, and GSE78220 were obtained from previously published articles and the Gene Expression Omnibus database. The different expressions of BMP1 in various clinical parameters were conducted, and prognostic analysis was executed utilizing Cox proportional hazard regression and Gene Expression Profiling Interactive Analysis. Moreover, the correlation between BMP1 and tumor microenvironment was analyzed using ESTIMATE and CIBERSORT algorithms. Tumor mutational burden and microsatellite instability were also included. The correlation between m6A modification and the gene expression level was analyzed using Tumor IMmune Estimation Resource, the University of Alabama at Birmingham Cancer data analysis portal. Gene Set Cancer Analysis analyzed the correlation of BMP1 expression level with copy number variations and methylation. Furthermore, the correlation between BMP1 and therapeutic response after antineoplastic drug use was illustrated for further discussion. Results. BMP1 expression had significant differences in 14 cancers. It presented an intimate relationship with immune-relevant biomarkers. A variation analysis indicated that BMP1 had a significant association with immunotherapeutic response. The expression level of BMP1 was closely associated with insulin-like growth factor binding protein 3, an m6A modification relative gene. Except for a few cancer types, methylation negatively correlated with BMP1, and copy number variations positively correlated with BMP1. Notably, low BMP1 expression was connected with immunotherapeutic response in the cohorts, and its expression was related to increased sectional sensitivity of drugs. Conclusion. BMP1 may serve as a potential biomarker for prognostic prediction and immunologic infiltration in diversified cancers, providing a new thought approach for oncotherapy.

METTL3 Modulates Ctsk+ Lineage Supporting Cranial Osteogenesis via Hedgehog

“…The Wnt/β-catenin pathway is regulated by m 6 A modification in cancer (Tabnak et al 2023) and during bone homeostasis (Huang et al 2021). The BMP signaling pathway is associated with m 6 A modification in immune infiltration in cancer (Zhou et al 2022). Our previous publication reveals that loss of METTL3 altered the gene set of the PTH/Pth1r signaling axis and caused osteoporosis in genetic mice model (Wu et al 2018).…”

Assessment of circulating proteins in thyroid cancer: Proteome-wide Mendelian randomization and colocalization analysis

“…BMP1 association with increased risk of TC offers insights into the role of bone morphogenetic proteins in cancer. 36 BMP1, multifunctional cytokines and members of the transforming growth factor β (TGF-β) family, 37 are involved in extracellular matrix organization, which might influence tumor microenvironment and malignant phenotypes in TC. 38 …”

Recent Advancements in Research on DNA Methylation and Testicular Germ Cell Tumors: Unveiling the Intricate Relationship

“…These genes showed different prognostic values, indicating tumor proliferation (e.g., FCER1G), immune infiltration, metastases, or poor overall survival, as summarized in Table 2. Some genes, such as BMP1, were upregulated and showed strong prognostic value for overall survival, progression-free survival, or tumor immune infiltration, but had a positive correlation with DNA methylation; thus, they did not correspond with the usual observations of gene hypomethylation-gene overexpression [61]. Another pan-cancer study showed that limb-bud and heart (LBH) was overexpressed in TCGT, and its levels were associated with poor prognosis [67].…”